TI
TVTX icon

Telemetry Investments’s Travere Therapeutics TVTX Stock Holding History

Telemetry Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20,000
Closed -$379K – 128
2016
Q4 		$379K Buy
+20,000
New +$409K 0.21% 61

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Telemetry Investments's TVTX Position: Q2 2019 in Review

Telemetry Investments sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 21,695 shares — an estimated $491K sold.

Telemetry Investments first reported a position in TVTX in Q4 2014 and held it in 16 quarters. The position peaked at $4.99M in Q2 2015. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

  • Telemetry Investments reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Telemetry Investments sold 21,695 Travere Therapeutics shares in Q2 2019, an estimated $491K.
  • Telemetry Investments first reported a position in Travere Therapeutics in Q4 2014 and held it in 16 quarters.
  • Telemetry Investments's Travere Therapeutics position peaked at $4.99M in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Telemetry Investments's 13F filing for Q2 2019, filed 14 Aug 2019.